829 related articles for article (PubMed ID: 23780684)
1. Androgen metabolite-dependent growth of hormone receptor-positive breast cancer as a possible aromatase inhibitor-resistance mechanism.
Hanamura T; Niwa T; Nishikawa S; Konno H; Gohno T; Tazawa C; Kobayashi Y; Kurosumi M; Takei H; Yamaguchi Y; Ito K; Hayashi S
Breast Cancer Res Treat; 2013 Jun; 139(3):731-40. PubMed ID: 23780684
[TBL] [Abstract][Full Text] [Related]
2. Possible role of the aromatase-independent steroid metabolism pathways in hormone responsive primary breast cancers.
Hanamura T; Niwa T; Gohno T; Kurosumi M; Takei H; Yamaguchi Y; Ito K; Hayashi S
Breast Cancer Res Treat; 2014 Jan; 143(1):69-80. PubMed ID: 24292869
[TBL] [Abstract][Full Text] [Related]
3. Induction of 3beta-hydroxysteroid dehydrogenase/delta5-delta4 isomerase type 1 gene transcription in human breast cancer cell lines and in normal mammary epithelial cells by interleukin-4 and interleukin-13.
Gingras S; Moriggl R; Groner B; Simard J
Mol Endocrinol; 1999 Jan; 13(1):66-81. PubMed ID: 9892013
[TBL] [Abstract][Full Text] [Related]
4. Interaction of Androst-5-ene-3β,17β-diol and 5α-androstane-3β,17β-diol with estrogen and androgen receptors: a combined binding and cell study.
Chen J; Wang WQ; Lin SX
J Steroid Biochem Mol Biol; 2013 Sep; 137():316-21. PubMed ID: 23416106
[TBL] [Abstract][Full Text] [Related]
5. Enhanced formation of non-phenolic androgen metabolites with intrinsic oestrogen-like gene transactivation potency in human breast cancer cells: a distinctive metabolic pattern.
Pérez-Palacios G; Santillán R; García-Becerra R; Borja-Cacho E; Larrea F; Damián-Matsumura P; González L; Lemus AE
J Endocrinol; 2006 Sep; 190(3):805-18. PubMed ID: 17003281
[TBL] [Abstract][Full Text] [Related]
6. The androgen metabolite 5alpha-androstane-3beta,17beta-diol (3betaAdiol) induces breast cancer growth via estrogen receptor: implications for aromatase inhibitor resistance.
Sikora MJ; Cordero KE; Larios JM; Johnson MD; Lippman ME; Rae JM
Breast Cancer Res Treat; 2009 May; 115(2):289-96. PubMed ID: 18521740
[TBL] [Abstract][Full Text] [Related]
7. Endogenous aromatization of testosterone results in growth stimulation of the human MCF-7 breast cancer cell line.
Sonne-Hansen K; Lykkesfeldt AE
J Steroid Biochem Mol Biol; 2005 Jan; 93(1):25-34. PubMed ID: 15748829
[TBL] [Abstract][Full Text] [Related]
8. 5alpha-Androstane-3beta,17beta-diol (3beta-diol), an estrogenic metabolite of 5alpha-dihydrotestosterone, is a potent modulator of estrogen receptor ERbeta expression in the ventral prostrate of adult rats.
Oliveira AG; Coelho PH; Guedes FD; Mahecha GA; Hess RA; Oliveira CA
Steroids; 2007 Dec; 72(14):914-22. PubMed ID: 17854852
[TBL] [Abstract][Full Text] [Related]
9. Androgen inactivation and steroid-converting enzyme expression in abdominal adipose tissue in men.
Blouin K; Richard C; Brochu G; Hould FS; Lebel S; Marceau S; Biron S; Luu-The V; Tchernof A
J Endocrinol; 2006 Dec; 191(3):637-49. PubMed ID: 17170221
[TBL] [Abstract][Full Text] [Related]
10. Role of androgens on MCF-7 breast cancer cell growth and on the inhibitory effect of letrozole.
Macedo LF; Guo Z; Tilghman SL; Sabnis GJ; Qiu Y; Brodie A
Cancer Res; 2006 Aug; 66(15):7775-82. PubMed ID: 16885381
[TBL] [Abstract][Full Text] [Related]
11. 5alpha-androstane-3alpha,17beta-diol supports human prostate cancer cell survival and proliferation through androgen receptor-independent signaling pathways: implication of androgen-independent prostate cancer progression.
Yang Q; Titus MA; Fung KM; Lin HK
J Cell Biochem; 2008 Aug; 104(5):1612-24. PubMed ID: 18320593
[TBL] [Abstract][Full Text] [Related]
12. Overcoming aromatase inhibitor resistance in breast cancer: possible mechanisms and clinical applications.
Hanamura T; Hayashi SI
Breast Cancer; 2018 Jul; 25(4):379-391. PubMed ID: 28389808
[TBL] [Abstract][Full Text] [Related]
13. Androgens upregulate cyp19a1b (aromatase B) gene expression in the brain of zebrafish (Danio rerio) through estrogen receptors.
Mouriec K; Gueguen MM; Manuel C; Percevault F; Thieulant ML; Pakdel F; Kah O
Biol Reprod; 2009 May; 80(5):889-96. PubMed ID: 19129512
[TBL] [Abstract][Full Text] [Related]
14. Expression of 3β-Hydroxysteroid Dehydrogenase Type 1 in Breast Cancer is Associated with Poor Prognosis Independent of Estrogen Receptor Status.
Chang YC; Chen CK; Chen MJ; Lin JC; Lin CH; Huang WC; Cheng SP; Chen SN; Liu CL
Ann Surg Oncol; 2017 Dec; 24(13):4033-4041. PubMed ID: 28744792
[TBL] [Abstract][Full Text] [Related]
15. Relative impact of androgen and estrogen receptor activation in the effects of androgens on trabecular and cortical bone in growing male mice: a study in the androgen receptor knockout mouse model.
Venken K; De Gendt K; Boonen S; Ophoff J; Bouillon R; Swinnen JV; Verhoeven G; Vanderschueren D
J Bone Miner Res; 2006 Apr; 21(4):576-85. PubMed ID: 16598378
[TBL] [Abstract][Full Text] [Related]
16. 5Alpha-reductase type 1 and aromatase in breast carcinoma as regulators of in situ androgen production.
Suzuki T; Miki Y; Moriya T; Akahira J; Ishida T; Hirakawa H; Yamaguchi Y; Hayashi S; Sasano H
Int J Cancer; 2007 Jan; 120(2):285-91. PubMed ID: 17066438
[TBL] [Abstract][Full Text] [Related]
17. Effects of steroidal aromatase inhibitors on sensitive and resistant breast cancer cells: aromatase inhibition and autophagy.
Amaral C; Varela C; Azevedo M; da Silva ET; Roleira FM; Chen S; Correia-da-Silva G; Teixeira N
J Steroid Biochem Mol Biol; 2013 May; 135():51-9. PubMed ID: 23318878
[TBL] [Abstract][Full Text] [Related]
18. Hormonal regulation of steroidogenic enzyme gene expression in Leydig cells.
Payne AH; Youngblood GL; Sha L; Burgos-Trinidad M; Hammond SH
J Steroid Biochem Mol Biol; 1992 Dec; 43(8):895-906. PubMed ID: 22217834
[TBL] [Abstract][Full Text] [Related]
19. Tumor-stromal interaction through the estrogen-signaling pathway in human breast cancer.
Yamaguchi Y; Takei H; Suemasu K; Kobayashi Y; Kurosumi M; Harada N; Hayashi S
Cancer Res; 2005 Jun; 65(11):4653-62. PubMed ID: 15930283
[TBL] [Abstract][Full Text] [Related]
20. New cell culture model for aromatase inhibitor-resistant breast cancer shows sensitivity to fulvestrant treatment and cross-resistance between letrozole and exemestane.
Hole S; Pedersen AM; Hansen SK; Lundqvist J; Yde CW; Lykkesfeldt AE
Int J Oncol; 2015 Apr; 46(4):1481-90. PubMed ID: 25625755
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
